CJC-1295 No DAC

A 29-residue synthetic peptide corresponding to the N-terminal fragment of a 44-residue hypothalamic peptide, carrying four stabilizing residue substitutions and a C-terminal amide.

Molecular Profile

Type
Synthetic peptide (tetrasubstituted, 29 residues)
Molecular formula
C152H252N44O42
Molecular weight
~3,368 g/mol
CAS number
863288-34-0
Amino acids
29
Sequence
H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Modification
Tetrasubstituted GRF(1-29) (D-Ala2, Gln8, Ala15, Leu27); C-terminal amide. The substitutions are positioned to resist DPP-IV cleavage, asparagine deamidation, and methionine oxidation. Unlike the DAC variant, it lacks the C-terminal albumin-binding maleimidopropionyl group.

Mechanism & Target Class

A 29-residue synthetic peptide corresponding to the N-terminal fragment (residues 1-29) of a 44-residue hypothalamic peptide, studied structurally in the context of class B1 G-protein-coupled receptor complexes. Four substitutions relative to the native fragment — D-Ala2, Gln8, Ala15, and Leu27 — confer greater enzymatic and chemical stability against DPP-IV cleavage, asparagine deamidation, and methionine oxidation. Because it lacks the DAC variant's albumin-binding group, it is short-circulating rather than long-circulating.

Storage & Handling

Lyophilized
-20°C; lyophilized peptide stored desiccated and protected from light.
Handling
Aliquot to avoid repeated freeze-thaw; protect from light and moisture. Storage conventions reflect supplier guidance for lyophilized peptides of this class.

Primary Database

PubChem CID 91976842 ↗

References (21)

  1. Reviews

    1

    Halmos G, et al. (2023). Vitamins and Hormones

    DOI: 10.1016/bs.vh.2023.06.004PubMed 37717982

  2. 2

    Campbell RM, Bongers J, Felix AM. (1995). Biopolymers

    DOI: 10.1002/bip.360370204PubMed 7893948

  3. 3

    Schally AV, et al. (2019). Endocrinology

    DOI: 10.1210/en.2019-00111PubMed 31070727

  4. Clinical

    4

    Sackmann-Sala L, et al. (2009). Growth Horm IGF Res

    DOI: 10.1016/j.ghir.2009.03.001PubMed 19386527

  5. 5

    Teichman SL, et al. (2006). J Clin Endocrinol Metab

    DOI: 10.1210/jc.2005-1536PubMed 16352683

  6. 6

    Ionescu M, Frohman LA. (2006). J Clin Endocrinol Metab

    DOI: 10.1210/jc.2006-1702PubMed 17018654

  7. 7

    ClinicalTrials.gov registry. ClinicalTrials.gov

    NCT00267527

  8. 8

    Chen RG, et al. (1993). Acta Paediatr Suppl

    DOI: 10.1111/j.1651-2227.1993.tb12834.xPubMed 8329830

  9. 9

    Neyzi O, et al. (1993). Acta Paediatr Suppl

    DOI: 10.1111/j.1651-2227.1993.tb12828.xPubMed 8329826

  10. Primary research

    10

    Zhou F, et al. (2020). Nat Commun

    DOI: 10.1038/s41467-020-18945-0PubMed 33060564

  11. 11

    Cai R, Schally AV, et al. (2014). Peptides

    DOI: 10.1016/j.peptides.2013.12.010PubMed 24373935

  12. 12

    Alba M, et al. (2006). Am J Physiol Endocrinol Metab

    DOI: 10.1152/ajpendo.00201.2006PubMed 16822960

  13. 13

    Jetté L, et al. (2005). Endocrinology

    DOI: 10.1210/en.2004-1286PubMed 15817669

  14. 14

    Dubreuil P, et al. (2001). Growth Horm IGF Res

    DOI: 10.1054/ghir.2001.0150PubMed 11735232

  15. 15

    Izdebski J, et al. (1995). Proc Natl Acad Sci USA

    DOI: 10.1073/pnas.92.11.4872

  16. 16

    Bongers J, et al. (1992). Int J Pept Protein Res

    DOI: 10.1111/j.1399-3011.1992.tb01596.x

  17. 17

    Friedman AR, et al. (1991). Int J Pept Protein Res

    DOI: 10.1111/j.1399-3011.1991.tb00727.xPubMed 1904406

  18. 18

    Frohman LA, et al. (1989). J Clin Invest

    DOI: 10.1172/JCI114049

  19. 19

    Lance VA, et al. (1984). Biochem Biophys Res Commun

    DOI: 10.1016/0006-291X(84)91647-4

  20. 20

    Stevenson CL, et al.. PubMed

    PubMed 8307680

  21. 21

    Cui T, et al. (2018). Oncotarget

    DOI: 10.18632/oncotarget.25676PubMed 29983893